Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
15 08 2019
Historique:
received: 15 04 2019
revised: 13 06 2019
accepted: 17 06 2019
pubmed: 27 6 2019
medline: 23 9 2020
entrez: 26 6 2019
Statut: ppublish

Résumé

The YAP-TEAD protein-protein interaction is a potential therapeutic target to treat cancers in which the Hippo signaling pathway is deregulated. However, the extremely large surface of interaction between the two proteins presents a formidable challenge for a small molecule interaction disrupter approach. We have accomplished progress towards showing the feasibility of this approach by the identification of a 15-mer peptide able to potently (nanomolar range) disrupt the YAP-TEAD interaction by targeting only one of the two important sites of interaction. This peptide, incorporating non-natural amino acids selected by structure-based design, is derived from the Ω-loop sequence 85-99 of YAP.

Identifiants

pubmed: 31235263
pii: S0960-894X(19)30402-0
doi: 10.1016/j.bmcl.2019.06.022
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Peptides 0
Small Molecule Libraries 0
Transcription Factors 0
YAP-Signaling Proteins 0
YAP1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2316-2319

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Pascal Furet (P)

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland. Electronic address: pascal.furet@novartis.com.

Bahaa Salem (B)

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Yannick Mesrouze (Y)

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Tobias Schmelzle (T)

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Ian Lewis (I)

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Joerg Kallen (J)

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Patrick Chène (P)

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH